CONNECTING PATIENTS TO ACTEMRA
Genentech is committed to helping patients access our medicines
If your patients:
If your patients:
Need help understanding health insurance coverage and related financial responsibilities, ACTEMRA Access Solutions is here to help.
Do not have health insurance coverage or have financial concerns and meet eligibility criteria, the Genentech Patient Foundation may be able to provide free medicine.*
Have health insurance and need help paying for their medicine, Affordability Options may be available.
†The final amount owed by patients may be as little as $5, but may vary depending on the patient’s health insurance plan. Eligible commercially insured patients who are prescribed ACTEMRA for an FDA-approved use can receive up to $15,000 in assistance annually for drug costs. See terms and conditions. Program limits apply.
Want information and resources about ACTEMRA, ACTEMRA & You™ provides answers to their questions.
*To be eligible for free Genentech medicine from the Genentech Patient Foundation, insured patients who have coverage for their medicine should try to pursue other forms of financial assistance, if available, and meet certain income requirements. Uninsured patients and insured patients without coverage for their medicine must meet a different set of income requirements.
†This ACTEMRA Co-pay Program is valid ONLY for patients with commercial insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medication. Patients using Medicare, Medicaid or any other federal or state government program to pay for their medications are not eligible.
Under the program, the patient will pay a co-pay. After reaching the maximum program benefit, the patient will be responsible for all remaining out-of-pocket expenses. The amount of the program benefit cannot exceed the patients’ out-of-pocket expenses for the cost associated with ACTEMRA.
All participants are responsible for reporting the receipt of all program benefits as required by any insurer or by law. No party may seek reimbursement for all or any part of the benefit received through this Program. The program is only valid in the United States and U.S. Territories. This program is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. The patient, guardian, prescriber, hospital and any other person using the program agree not to seek reimbursement for all or any part of the benefit received by the patient through the offer of this program. Genentech reserves the right to rescind, revoke or amend the program without notice at any time. Additional terms and conditions apply. Please visit RACopay.com for the full list of Terms and Conditions.
‡Independent co-pay assistance foundations have their own rules for eligibility. Genentech has no involvement or influence in independent foundation decision-making or eligibility criteria and does not know if a foundation will be able to help your patient. We can only refer your patient to a foundation that supports their disease state. Genentech does not endorse or show preference for any particular foundation. The foundations to which we refer your patient may not be the only ones that might be able to help.
RA=rheumatoid arthritis; SC=subcutaneous.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
ACTEMRA [package insert]. South San Francisco, CA: Genentech, Inc.
Jones G, et al. Ann Rheum Dis. 2010;69:88-96.
Jones G, et al. Ann Rheum Dis. 2010;69:88-96.
Kremer JM, et al. Arthritis Rheumatol. 2018;70(8):1200-1208.
Kremer JM, et al. Arthritis Rheumatol. 2018;70(8):1200-1208.
Maini RN, et al. Arthritis Rheum. 2006;54(9):2817-2829.
Maini RN, et al. Arthritis Rheum. 2006;54(9):2817-2829.
Bykerk VP, et al. Ann Rheum Dis. 2012;71:1950-1954.
Bykerk VP, et al. Ann Rheum Dis. 2012;71:1950-1954.
Dougados M, et al. Ann Rheum Dis. 2013;72:43-50.
Dougados M, et al. Ann Rheum Dis. 2013;72:43-50.
Weinblatt ME. Arthritis Care Res. 2013;65(3):362-371.
Weinblatt ME. Arthritis Care Res. 2013;65(3):362-371.
Ogata A, et al. Arthritis Care Res. 2014;66(3):344-354.
Ogata A, et al. Arthritis Care Res. 2014;66(3):344-354.
Gabay C, et al. Lancet. 2013;381:1541-1550.
Gabay C, et al. Lancet. 2013;381:1541-1550.
Emery P, et al. Ann Rheum Dis. 2008;67:1516-1523.
Emery P, et al. Ann Rheum Dis. 2008;67:1516-1523.
Burmester GR, et al. Ann Rheum Dis. 2014;73:69-74.
Burmester GR, et al. Ann Rheum Dis. 2014;73:69-74.
Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.
Kremer JM, et al. Arthritis Rheum. 2011;63(3):609-621.
Genovese MC, et al. Arthritis Rheum. 2008;58(10):2968-2980.
Genovese MC, et al. Arthritis Rheum. 2008;58(10):2968-2980.
Data on file. Clinical Study Report. Genentech, Inc.
Data on file. Clinical Study Report. Genentech, Inc.
Kivitz A, et al. Arthritis Care Res. 2014;66(11):1653-1661.
Kivitz A, et al. Arthritis Care Res. 2014;66(11):1653-1661.
Smolen JS, et al. Arthritis Rheum. 2006;54:702-710.
Smolen JS, et al. Arthritis Rheum. 2006;54:702-710.
De Benedetti F, et al. N Engl J Med. 2012;367:2385-2395.
De Benedetti F, et al. N Engl J Med. 2012;367:2385-2395.
Brunner HI, et al. Ann Rheum Dis. 2015;74:1110-1117.
Brunner HI, et al. Ann Rheum Dis. 2015;74:1110-1117.
Yazici Y, et al. Ann Rheum Dis. 2012;71:198-205.
Yazici Y, et al. Ann Rheum Dis. 2012;71:198-205.
Bingham CO, et al. Ann Rheum Dis. 2014;74:818-822.
Bingham CO, et al. Ann Rheum Dis. 2014;74:818-822.
Smolen JS, et al. Lancet. 2008;371:987-997.
Smolen JS, et al. Lancet. 2008;371:987-997.
Scheller J, et al. Med Microbiol Immunol. 2006;195:173-183.
Scheller J, et al. Med Microbiol Immunol. 2006;195:173-183.
McGrath H, et al. Rheumatology. 2004;43:1323-1325.
McGrath H, et al. Rheumatology. 2004;43:1323-1325.
Browning JL, et al. Nat Rev Discov. 2006;5:564-576.
Browning JL, et al. Nat Rev Discov. 2006;5:564-576.
Choy E, et al. Rheum Dis Clin N Am. 2004;30:405-415.
Choy E, et al. Rheum Dis Clin N Am. 2004;30:405-415.
Data on file. LITHE Clinical Study Report. Genentech, Inc.
Data on file. LITHE Clinical Study Report. Genentech, Inc.
Data on file. ACTEMRA Studies Matrix. Genentech, Inc.
Data on file. ACTEMRA Studies Matrix. Genentech, Inc.
Data on file. PBRER Core Report. Genentech, Inc.
Data on file. PBRER Core Report. Genentech, Inc.
Data on file, Genentech, Inc.
Data on file, Genentech, Inc.
Genentech Analysis of Managed Markets Insight & Technology (MMIT) Data.
Genentech Analysis of Managed Markets Insight & Technology (MMIT) Data.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.